BNP Paribas Financial Markets Buys 208,552 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

BNP Paribas Financial Markets increased its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 248.0% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 292,629 shares of the specialty pharmaceutical company's stock after buying an additional 208,552 shares during the period. BNP Paribas Financial Markets owned 0.53% of Supernus Pharmaceuticals worth $10,581,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in SUPN. Smartleaf Asset Management LLC raised its holdings in Supernus Pharmaceuticals by 219.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after purchasing an additional 870 shares during the period. Mark Sheptoff Financial Planning LLC bought a new stake in Supernus Pharmaceuticals during the fourth quarter valued at about $52,000. Headlands Technologies LLC raised its holdings in Supernus Pharmaceuticals by 203.0% during the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock valued at $55,000 after acquiring an additional 1,015 shares during the period. Newbridge Financial Services Group Inc. bought a new stake in Supernus Pharmaceuticals during the fourth quarter valued at about $72,000. Finally, Venturi Wealth Management LLC bought a new stake in Supernus Pharmaceuticals during the fourth quarter valued at about $92,000.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN traded down $0.74 during trading on Wednesday, hitting $31.54. The stock had a trading volume of 423,213 shares, compared to its average volume of 492,648. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of 29.48 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $40.28. The stock has a 50 day simple moving average of $31.86 and a 200 day simple moving average of $34.85.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the firm's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now owns 7,853 shares of the company's stock, valued at $307,444.95. This trade represents a 10.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 9.30% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on SUPN shares. StockNews.com lowered Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. Cantor Fitzgerald restated a "neutral" rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.